Janus

First Trust Announces Shareholder Approval of First Trust Dynamic Europe Equity Income Fund’s Reorganization into First Trust Active Global Quality Income ETF

Retrieved on: 
Monday, October 23, 2023

As previously announced, the reorganization was approved by the Boards of Trustees of FDEU and AGQI on March 22, 2023.

Key Points: 
  • As previously announced, the reorganization was approved by the Boards of Trustees of FDEU and AGQI on March 22, 2023.
  • Subject to the satisfaction of certain customary closing conditions, the reorganization of FDEU into AGQI is expected to close on or around November 20, 2023.
  • FDEU is a diversified, closed-end management investment company that seeks to provide a high level of current income with a secondary focus on capital appreciation.
  • AGQI is an actively managed ETF that seeks income with the potential for capital growth over the longer-term.

LEO Pharma Presents Adbry® (tralokinumab-ldrm) Data at 2023 Fall Clinical Dermatology Conference

Retrieved on: 
Friday, October 20, 2023

LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of new clinical and real-world data around tralokinumab-ldrm in the treatment of moderate-to-severe atopic dermatitis (AD).

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of new clinical and real-world data around tralokinumab-ldrm in the treatment of moderate-to-severe atopic dermatitis (AD).
  • The drug is marketed in the U.S. as Adbry® for adult patients (aged 18+ years) with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
  • The findings are being presented across 12 posters at the 2023 Fall Clinical Dermatology Conference taking place in Las Vegas, Nevada, from October 19-22, 2023.1-12
    “We are thrilled to present such a wealth of tralokinumab-ldrm data, which will further develop our understanding of how to meet the needs of patients living with atopic dermatitis,” says Kreesten Meldgaard Madsen, Chief Development Officer, LEO Pharma.
  • “The breadth and depth of LEO Pharma data being presented at the Fall Clinical Dermatology Conference this year will showcase our leadership in the medical dermatology space and our continued commitment to the whole patient community.

 Janus Henderson’s pioneering AAA CLO ETF surpasses $4 billion in AUM before third anniversary

Retrieved on: 
Wednesday, October 18, 2023

Janus Henderson Investors (NYSE/AX: JHG) today announced that its pioneering AAA Collateralized Loan Obligation ETF, Janus Henderson AAA CLO ETF (JAAA), has surpassed $4 billion in AUM before its third anniversary, making it the largest fixed income ETF launch as measured by AUM, active or passive, of the last three years, according to Bloomberg data.

Key Points: 
  • Janus Henderson Investors (NYSE/AX: JHG) today announced that its pioneering AAA Collateralized Loan Obligation ETF, Janus Henderson AAA CLO ETF (JAAA), has surpassed $4 billion in AUM before its third anniversary, making it the largest fixed income ETF launch as measured by AUM, active or passive, of the last three years, according to Bloomberg data.
  • * Janus Henderson is now the fifth largest provider of active fixed income ETFs in the U.S by AUM as of October 16, 2023.
  • Janus Henderson has been at the forefront of active fixed income ETF innovation, offering a number of fixed income ETFs.
  • Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiaries.

2023 ITRI ICT TechDay Focusing on LEO Satellites, IoV, Cyber Security, 5G Communications, and GAI

Retrieved on: 
Tuesday, October 17, 2023

HSINCHU, Oct. 17, 2023 /PRNewswire/ -- The 2023 ITRI ICT TechDay, an all-day forum and technology exhibition, showcased groundbreaking information and communication innovations with a focus on low Earth orbit (LEO) Satellites, the Internet of Vehicles (IoV), 5G/6G communications, cyber security, and generative AI (GAI).

Key Points: 
  • HSINCHU, Oct. 17, 2023 /PRNewswire/ -- The 2023 ITRI ICT TechDay, an all-day forum and technology exhibition, showcased groundbreaking information and communication innovations with a focus on low Earth orbit (LEO) Satellites, the Internet of Vehicles (IoV), 5G/6G communications, cyber security, and generative AI (GAI).
  • Innovations promoting openness, intelligence, and green have emerged as the driving forces behind ICT development, fostering the growth of startups that are injecting new energy into Taiwan's ICT industry.
  • Taiwan's ICT companies independently completed the LEO satellite ground equipment architecture and interface design, positioning them among the top three satellite manufacturers globally.
  • Several healthcare institutions, smart factories, and electric vehicle charging infrastructure in Taiwan have embraced Janus to boost cyber security.

First Trust Dynamic Europe Equity Income Fund Issues Notice Regarding October 2023 Distribution

Retrieved on: 
Monday, October 16, 2023

The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital.

Key Points: 
  • The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital.
  • A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income."
  • The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.
  • First Trust Advisors L.P. ("FTA") is a federally registered investment advisor and serves as the Fund's investment advisor.

LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE) at EADV 2023

Retrieved on: 
Friday, October 13, 2023

DELTA 2 is the second of two pivotal phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).1,4

Key Points: 
  • DELTA 2 is the second of two pivotal phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).1,4
    DELTA 2 was a randomized, double-blind, cream vehicle-controlled trial.
  • Adults were randomized to either twice-daily delgocitinib cream (n=314) or cream vehicle (n=159) for 16 weeks followed by a separate 36-week extension trial.
  • “Through assessment of the DELTA 1 and DELTA 2 trial results, we aim to assess the efficacy and safety of delgocitinib cream in adults living with this hard-to-treat disease."
  • “This latest collection of clinical data for delgocitinib cream supports LEO Pharma’s unwavering commitment to addressing the critical unmet need in CHE,” says Kreesten Meldgaard Madsen, Chief Development Officer, LEO Pharma.

U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)

Retrieved on: 
Friday, October 13, 2023

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).

Key Points: 
  • Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).
  • Nearly two-thirds of patients in ELEVATE UC 52 and ELEVATE UC 12 were naïve to biologic or JAK inhibitor therapy, and these studies were also the only studies for advanced therapies for ulcerative colitis to include patients with isolated proctitis.
  • Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of VELSIPITY.
  • “Because of the unpredictable nature of UC, people living with the disease can cycle through several different treatments over time.

Nokē Migrates to AWS to Enhance Cloud-Based, Digital Customer Experience

Retrieved on: 
Wednesday, October 11, 2023

This successful migration allows Nokē to continue to lead digital innovation by leveraging AWS’s leading industrial internet of things (IoT), artificial intelligence, and security capabilities.

Key Points: 
  • This successful migration allows Nokē to continue to lead digital innovation by leveraging AWS’s leading industrial internet of things (IoT), artificial intelligence, and security capabilities.
  • Running on AWS, Nokē has increased its availability and global reach, enabled real-time over-the-air device management, and improved the owner-operator and end-user experience through latency reduction and improved data synchronization.
  • Sanjay Khinvasara, EVP & Chief Engineering Officer of Nokē, said of the project, “We moved our entire customer base to AWS to take advantage of the stability and functionality of the world’s leading cloud provider.
  • The award-winning Nokē offering includes smart keypads and smart locks, as well as the Nokē cloud-based software and mobile app.

Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis

Retrieved on: 
Monday, October 16, 2023

SHANGHAI, Oct. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).

Key Points: 
  • SHANGHAI, Oct. 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).
  • Everest is conducting a multi-center Phase 3 clinical trial of etrasimod in Asia and aims to file New Drug Application as soon as possible.
  • "Etrasimod's FDA approval marks an important milestone for moderately to severely active UC patients who need new treatments for this chronic condition.
  • Everest Medicines obtained exclusive rights from Arena to develop, manufacture and commercialize etrasimod in Greater China and South Korea in 2017.

Janus Henderson to Report Third Quarter 2023 Results

Retrieved on: 
Friday, October 6, 2023

Janus Henderson Group plc (NYSE/ASX: JHG) will announce its third quarter 2023 results on Wednesday, November 1, 2023, at 5 a.m. EDT, 9 a.m. GMT, 8 p.m. AEDT.

Key Points: 
  • Janus Henderson Group plc (NYSE/ASX: JHG) will announce its third quarter 2023 results on Wednesday, November 1, 2023, at 5 a.m. EDT, 9 a.m. GMT, 8 p.m. AEDT.
  • A conference call and webcast to discuss the results will be held at 8 a.m. EDT, 12 p.m. GMT, 11 p.m. AEDT.
  • Those wishing to participate in the conference call should call the applicable number below and reference the Janus Henderson Results Briefing (Conference ID: 689806):
    To eliminate wait times, conference call participants may pre-register at.
  • Access to the live webcast and accompanying slides will be available via the investor relations section of Janus Henderson’s website (ir.janushenderson.com); a webcast replay will be available following the call.